New

Global ETF Survey 2026: Answer now →

Help us improve your experience. Please confirm your investor type:

Global ETF Survey 2026

The ETF Industry Is Evolving Fast

From AI infrastructure to active strategies, the ETF landscape is shifting. Share your perspective in the 7th Annual Global ETF Survey.

Global ETF Survey 2026
ETF IssuersGlobal XGNOM
GNOM

Global X Genomics & Biotechnology ETF

The GNOM Exchange Traded Fund (ETF) is provided by Global X. It is built to track an index: Solactive Genomics Index. The GNOM ETF provides physical exposure, so by buying it you actually own parts of all the 50 underlying holdings. This share class generates a stream of income by distributing dividends.

Advertisement

Advertisement

$58.17
+$2.5 (+4.43%) yesterday
1:30 PM 08/07/26 Closed
1D price range
$57.08$58.26
52W price range
$8.77$58.93
YTD Perf.
+28.02%
YTD Flows
Annualized volatility
Fund AuM
€74M
Share class AuM
€74M
TTM Yield
Tracking Error
Tracking Difference
ISIN
US37960A2143
TER
0.5%
Inception date
4/5/2019
Issuer
Replication method
Dividend policy
Compare similar ETFs
API
PerformanceDec 31, 2025 - Aug 7, 2026
-10%0%10%20%30%JANMARMAYJUL
Flows
Join for free to unlock
Data as of 06/30/26
Healthcare
99.75%
Other
0.25%
Latest GNOM news

FAQ about GNOM

GNOM is a Passive ETF. This ETF provides exposure to Equities.
GNOM tracks the Solactive Genomics Index - USD, through a full replication replication method.
GNOM carries a total expense ratio (TER) of 0.5%, indicating the annual cost for holding the fund.
GNOM was introduced to the market on April 5, 2019. It trades on United States
Global X Genomics & Biotechnology ETF, GNOM, is provided by Global X. Learn more about Global X here.
GNOM oversees €74M in assets as of August 7, 2026.
GNOM follows a distributing dividend policy, meaning it pays out income to investors. As of August 7, 2026, its 12-month trailing yield was 1.11%.
As of June 30, 2026, GNOM has significant geographic allocations in USA, Netherlands and Switzerland.
As of June 30, 2026, GNOM focuses largely on Healthcare.
As of June 30, 2026, GNOM holds 50 positions in its portfolio, with 61.22% of assets concentrated in its top 15 holdings.
As of June 30, 2026, GNOM top three holdings include Guardant Health, Inc., Twist Bioscience Corp. and Illumina, Inc..
The base currency of GNOM is USD.
Data as of 06/30/26
Guardant Health, Inc.
5.78%
Twist Bioscience Corp.
5.09%
Illumina, Inc.
4.67%
Natera, Inc.
4.41%
Moderna, Inc.
4.22%
Veracyte, Inc.
4.12%
Bio-Techne Corp.
4.08%
Vertex Pharmaceuticals, Inc.
3.85%
Legend Biotech Corp.
3.82%
10X Genomics, Inc.
3.70%

Trackinsight
Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:
  • More fund data
  • Compare up to 3 funds
  • More screener filters
  • Edit screener columns from 100+ metrics
  • Watchlists for saving your research
  • Portfolio construction and analysis
  • Personal dashboard for live monitoring

Advertisement

Trackinsight

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy  |  Cookie policy  |    |  Terms of use  |  Imprint
Trackinsight